Step right up: A biotech may soon sell an experimental med to dying ALS patients under 'Right to Try'
During the debate over the new Right to Try legislation, a number of critics raised the argument that some companies would try to cash in by selling experimental drugs with an undefined risk profile to desperate, dying patients.
Brainstorm Cell Therapeutics $BCLI appears to be on track to be one of the first to test the letter of the law on that score.
The Israeli biotech has been slowly working on a stem cell therapy for ALS, or Lou Gehrig’s disease. For months now, company execs have been hinting at the move, noting the number of ALS patients who have been clamoring for a therapy they dubbed NurOwn. And in an interview with Bloomberg, CEO Chaim Lebovits said that they’re thinking of a price in the region of the pioneering personalized cell therapies that have been approved.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters